Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 6:05 pm Purchase | 2023-12-18 | 13G | Neurogene Inc. NGNE | EcoR1 Capital, LLC | 1,282,168 9.990% | 1,282,168 (New Position) | Filing History |
| 2024-02-14 4:37 pm Purchase | 2023-12-31 | 13G | Neurogene Inc. NGNE | Great Point Partners, LLC | 994,229 7.750% | 25,000 (+2.58%) | Filing History |
| 2024-02-14 4:26 pm Purchase | 2023-12-31 | 13G | Neurogene Inc. NGNE | Redmile Group, LLC | 1,050,304 8.100% | 1,050,304 (New Position) | Filing History |
| 2024-02-14 4:16 pm Purchase | 2023-12-18 | 13G | Neurogene Inc. NGNE | Samsara BioCapital, L.P. | 1,282,563 9.990% | 1,282,563 (New Position) | Filing History |
| 2024-02-14 3:08 pm Purchase | 2023-12-31 | 13G | Neurogene Inc. NGNE | Cormorant Asset Management, LP | 746,180 5.820% | 746,180 (New Position) | Filing History |
| 2024-02-14 2:02 pm Purchase | 2023-12-31 | 13G | Neurogene Inc. NGNE | JANUS HENDERSON GROUP PLC JHG | 841,688 6.600% | 841,688 (New Position) | Filing History |
| 2024-02-14 09:19 am Sale | 2023-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | LYNX1 CAPITAL MANAGEMENT LP | 46 0.100% | -114,511 (-99.96%) | Filing History |
| 2023-12-27 4:03 pm Purchase | 2023-12-18 | 13G | Neurogene Inc. NGNE | Great Point Partners, LLC | 969,229 7.560% | 969,229 (New Position) | Filing History |
| 2023-12-22 4:15 pm Purchase | 2023-12-18 | 13G | Neoleukin Therapeutics, Inc. NLTX | Redmile Group, LLC | 1,282,661 9.900% | 1,282,661 (New Position) | Filing History |
| 2023-12-21 4:05 pm Purchase | 2023-12-18 | 13D | Neurogene Inc. NGNE | McMinn Rachel | 1,273,351 9.900% | 1,273,351 (New Position) | Filing History |
| 2023-12-20 5:24 pm Purchase | 2023-12-18 | 13D | Neurogene Inc. NGNE | Baker Bros. Advisors LP | 649,685 4.990% | 649,685 (New Position) | Filing History |
| 2023-10-10 4:42 pm Purchase | 2023-10-05 | 13D | Neoleukin Therapeutics, Inc. NLTX | Baker Bros. Advisors LP | 473,667 19.990% | 473,667 (New Position) | Filing History |
| 2023-08-17 5:12 pm Sale | 2023-08-15 | 13D | Neoleukin Therapeutics, Inc. NLTX | Baker Bros. Advisors LP | 473,605 19.990% | -28,549 (-5.69%) | Filing History |
| 2023-07-27 5:15 pm Sale | 2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX | Redmile Group, LLC | 145,611 6.600% | -5,917 (-3.90%) | Filing History |
| 2023-07-19 5:28 pm Purchase | 2023-07-17 | 13D | Neoleukin Therapeutics, Inc. NLTX | Baker Bros. Advisors LP | 502,154 19.990% | 290,663 (+137.43%) | Filing History |
| 2023-02-14 4:21 pm Sale | 2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Redmile Group, LLC | 151,528 6.900% | -64,550 (-29.87%) | Filing History |
| 2023-02-03 11:56 am Sale | 2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | PICTET ASSET MANAGEMENT SA | 0 0.000% | -128,714 (Position Closed) | Filing History |
| 2023-01-19 4:10 pm Sale | 2022-12-31 | 13G | Neoleukin Therapeutics, Inc. NLTX | Integrated Core Strategies (Asia) Pte. Ltd. | 79,363 3.700% | -27,266 (-25.57%) | Filing History |
| 2022-12-30 4:29 pm Purchase | 2022-12-20 | 13G | Neoleukin Therapeutics, Inc. NLTX | LYNX1 CAPITAL MANAGEMENT LP | 114,557 5.380% | 114,557 (New Position) | Filing History |
| 2022-07-19 4:08 pm Purchase | 2022-07-18 | 13G | Neoleukin Therapeutics, Inc. NLTX | Integrated Core Strategies (Asia) Pte. Ltd. | 106,629 5.000% | 1,058 (+1.00%) | Filing History |